Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient

Abstract

In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with PD-1 inhibition (pembrolizumab).

Keywords

• sjögren’s syndrome
• sicca syndrome
• pembrolizumab
• immune checkpoint inhibition
• non-small cell lung carcinoma
• immune-related adverse event
• case report